Amarin's (AMRN) Q4 Earnings And Sales Surpass Estimates
Zacks Investment Research | Feb 25, 2020 09:16PM ET
Amarin Corporation PLC (NASDAQ:AMRN) reported fourth-quarter 2019 adjusted earnings of 4 cents (excluding stock based compensation) per American depositary share, beating the Zacks Consensus Estimate of 1 cent. The company had recorded an adjusted loss of 9 cents in the year-ago period.
Revenues, primarily from its sole marketed drug Vascepa, were up almost 85.3% year over year to $143.3 million in the quarter, beating the Zacks Consensus Estimate of $134.44 million.
Despite strong fourth-quarter results, shares of Amarin were down 2% in after-hours trading on Feb 25, possibly due to significant decline in the broader S&P 500 Index. The stock has declined 12.6% in the past year compared with the approved a label expansion for Vascepa as a treatment to reduce cardiovascular risk in patients with persistent elevated triglycerides on statin therapy for LDL-C (bad cholesterol). The approval was based on the results of the REDUCE-IT cardiovascular outcomes (“CVOT”) study. The drug is under review for a similar indication in Europe. Please note that the drug is not approved any indication in Europe.
Licensing revenues were $1.2 million in the fourth quarter compared with $0.24 million in the year-ago period.
Selling, general and administrative expenses were up 20.5% to $96 million due to rise in commercial and other promotional costs to support launch of Vascepa in expanded label.
Research & development expenses decreased 6.8% to $11.1 million due to a decline in costs, following completion of REDUCE-IT study.
The company ended the quarter with $664.6 million in cash and cash equivalents, compared with $673.2 million as of Sep 30, 2019.
Full-Year Results
Amarin reported revenues of $429.8 million, up 87.5% year over year. The company’s adjusted earnings for 2019 were 2 cents per share against a loss of 33 cents in the year-ago period.
Revenues for the full year as well as the reported quarter were at the highest level recorded by the company.
Vascepa Update
Amarin increased its sales force through 2019 to support the launch of Vascepa’s label expansion. It has doubled its sales team compared to 2019 and is planning to increase targeted healthcare professionals from 50,000 to 75,000.
On its fourth-quarter earnings call, Amarin stated that payer coverage for Vascepa has improved in 2020 with expanded coverage by various payers in January and February. The company expects coverage to improve further in the coming months.
In January 2020, the company announced the approval for Vascepa in Canada to reduce the risk of cardiovascular events in statin-treated patients with elevated triglycerides based on REDUCE-IT study data. Its commercial partner in Canada has started promoting Vascepa in the country.
2020 Guidance Maintained
Amarin had provided guidance for revenues and operating expenses with its preliminary results announced in January 2020. It maintained the view on its fourth quarter earnings call.
The company continues to expect revenues for 2020 to be in the range of $650-$700 million, primarily from Vascepa sales, indicating growth of 57% year over year at the mid-point of the range. The company remains on track to increase its sales team to approximately 800 in early 2020. It expects its operating expense to increase approximately to $200 to $250 million from expenses incurred in 2019, especially to support its increased sales team and various promotional programs related to Vascepa.
The company had announced in its preliminary results that it anticipates cash flow to remain negative in the beginning of 2020. Meanwhile, the company stated that it has sufficient funds to maintain projected operations and to achieve positive cash flow following the commercial launch of Vascepa in the expanded label.
Our Take
Amarin reported impressive results with both fourth-quarter earnings and revenues beating estimates. Moreover, sales of Vascepa continued on its strong growth path. The projected sales growth for 2020 also indicates growth trend to continue. U.S. label expansion, Canadian approval and improved payer coverage for Vascepa as well as increased sales force support the strong outlook. The company believes Vascepa has multi-billion dollar potential.
Meanwhile, discontinuation of a CVOT study by AstraZeneca (NYSE:AZN) last month on Epanova, an omega-3 based drug like Vascepa and a possible strong competitor, further boosts Vascepa's prospects.
Get The News You Want
Amarin Corporation PLC Price, Consensus and EPS Surprise
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.